Halozyme Therapeutics
HALO • NASDAQ
Halozyme Therapeutics is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Helen I. Torley, with a market cap of $9.2B.
CEOHelen I. Torley
Market Cap$9.2B
Biotechnology
Healthcare
Employees373.0
Websitehalozyme.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Halozyme Therapeutics
Date
Tuesday, May 5, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
$1.69
Revenue Estimate
$375.6M
Earnings History
Past 11 earnings reports for Halozyme Therapeutics
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | Q3 2025 | $1.72Est: $1.58 | +8.9% | $354.3MEst: $338.3M | +4.7% |  10-Q |
| Aug 5, 2025 | Q2 2025 | $1.54Est: $1.20 | +28.3% | $325.7MEst: $286.0M | +13.9% | 10-Q |
| May 6, 2025 | Q1 2025 | $1.11Est: $0.94 | +18.1% | $264.9MEst: $230.2M | +15.1% | 10-Q |
| Feb 18, 2025 | Q4 2024 | $1.26Est: $1.16 | +8.6% | $298.0MEst: $285.7M | +4.3% | 10-K |
| Oct 31, 2024 | Q3 2024 | $1.27Est: $0.98 | +29.6% | $290.1MEst: $251.1M | +15.5% | 10-Q |
| Aug 6, 2024 | Q2 2024 | $0.91Est: $0.78 | +16.7% | $231.4MEst: $208.9M | +10.7% | 10-Q |
| May 7, 2024 | Q1 2024 | $0.79Est: $0.69 | +14.5% | $195.9MEst: $199.8M | -2.0% | 10-Q |
| Feb 20, 2024 | Q4 2023 | $0.82Est: $0.83 | -1.2% | $230.0MEst: $233.2M | -1.4% | 10-K |
| Nov 6, 2023 | Q3 2023 | $0.75Est: $0.73 | +2.7% | $216.0MEst: $222.6M | -3.0% | — |
| Aug 8, 2023 | Q2 2023 | $0.74Est: $0.63 | +17.5% | $221.0MEst: $199.3M | +10.9% | 10-Q |
| May 9, 2023 | Q1 2023 | $0.47Est: $0.48 | -2.1% | $162.1MEst: $175.5M | -7.6% | 10-Q |